Neurophet Set to Showcase Innovative AI Solutions at SNMMI 2025

Neurophet to make a significant mark at SNMMI 2025

Neurophet, a leading innovator in artificial intelligence solutions for brain disorders, will be at the forefront of the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 conference, scheduled from June 21-24 in New Orleans, USA. The Co-CEOs, Jake Junkil Been and Donghyeon Kim, are excited to present their groundbreaking product, the Neurophet SCALE PET, which promises to change the landscape of brain imaging analysis.

Showcasing Neurophet SCALE PET

The highlight of Neurophet's participation will be the showcase of the Neurophet SCALE PET. This advanced software solution specializes in the quantitative analysis of Positron Emission Tomography (PET) images. By integrating imaging data from PET and Magnetic Resonance Imaging (MRI), Neurophet SCALE PET offers precise analysis of various brain biomarkers which are critical in understanding neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease.

Understanding brain metabolism and neurotransmitter activity through PET imaging is pivotal, especially in the early stages of these diseases where traditional structural imaging methods may fall short. Neurophet SCALE PET automatically calculates Standardized Uptake Value Ratios (SUVR), facilitating early detection of abnormalities—a critical factor in forming individualized treatment plans for patients.

Essential for Diagnosing Neurodegenerative Disorders

The application of Neurophet SCALE PET allows for a deeper insight into brain health. By measuring biomarkers associated with cognitive decline, including amyloid-beta and tau proteins, practitioners can identify crucial changes in brain metabolism. The SUVR values play an instrumental role in quantifying these biomarkers, helping clinicians make informed decisions based on comprehensive data.

Additionally, Neurophet's participation at SNMMI 2025 will not stop at showcasing SCALE PET. The company also plans to unveil Neurophet AQUA AD, a software solution specifically designed for enhanced treatment management of Alzheimer’s disease. AQUA AD supports healthcare providers in making informed prescriptions while closely monitoring the effectiveness of therapies and their side effects.

Fostering Global Collaborations

An essential part of Neurophet's participation at the conference will be engaging with leaders in the pharmaceutical industry and developers of radiopharmaceuticals. With the increasing demand for AI-driven imaging solutions, Neurophet aims to solidify strategic partnerships that could facilitate collaborative ventures in the development and application of their technologies.

“Our goal with attendance at SNMMI 2025 is to deepen our business relationships within the medical community globally. We anticipate meaningful discussions with key stakeholders in the PET imaging sector,” remarked Jake Junkil Been, Co-CEO of Neurophet.

About Neurophet

Founded in 2016, Neurophet has been at the cutting edge of AI innovations for diagnosing and treating brain disorders. Their product portfolio includes not only the Neurophet SCALE PET and AQUA AD but also advanced solutions for other neurological applications like tES/TMS LAB for brain stimulation treatment planning, and multiple sclerosis imaging analysis software.

As Neurophet continues to lead efforts in redefining brain health diagnosis through AI, their commitment to improving the lives of patients with brain disorders remains their top priority. The firm embodies a forward-thinking approach that unites technological advancement with compassionate patient care, setting high standards in the healthcare sector.

Attending SNMMI 2025 marks a pivotal moment for Neurophet, as it seeks to expand its impact on global healthcare and innovate pathways for enhanced brain health solutions.